加强口腔门诊消毒隔离管理

加强口腔门诊的消毒隔离管理，有效切断传播途径，避免交叉感染，预防和控制院内感染。为医生给病人安全治疗提供保障，也为病员提供良好、舒适、安全、放心的就诊环境。     

微创经皮钢板骨桥接术联合锁定加压钛板治疗胫骨远端骨折

目的探讨微创经皮钢板骨桥接术（minimallyi nvasive percutaneous plate osteosynthesis，MIPPO）联合锁定加压钛板（locking compression plate，LCP）治疗胫骨远端骨折的近期疗效。方法2004年6月～2006年3月采用MIPPO联合LCP治疗胫骨远端骨折16例，AO分型：43A1型7例，43A3型5例，43B1型2例，43C3型2例。采用3种方法复位胫骨骨折后插入LCP，用锁定螺钉固定。结果16例随访5～20个月，平均11，5月。16例切口一期愈合，骨折无延迟愈合、畸形愈合、断钉、断板等并发症。术后X线检查4～12周（平均7．6周）骨痂形成并开始部分负重，8～20周骨性愈合（平均16周），此时开始完全负重。3例出现胫骨远端内植物局部不适。根据美国足踝骨科学会评分系统对踝关节功能评分，优14例（87．5％），良2例（12，5％）。结论MIPPO具有创伤小、固定牢靠、可早期功能锻炼等优点，近期疗效满意，是治疗胫骨远端骨折的有效方法。     

推拿并牵引治疗腰椎间盘突出症230例

笔者2006年3月～2008年5月应用牵引配合手法推拿治疗腰椎间盘突出症230例，收到满意疗效，总结如下。     

造影剂到达腹主动脉的峰值大小与患者因素的关系

目的探讨造影剂到达腹主动脉的峰值大小与患者因素之间的关系。方法108例患者以2.5ml/s注射欧乃派克(300mgI/ml)20ml,12s后采用testbolus技术在腹腔干水平同层动态扫描腹主动脉,用dynamic evaluation软件测得腹主动脉的峰值大小,采用单因素回归分析和多因素逐步回归分析法研究患者的性别、年龄、身高、体重、心率、血压、注射位点、达峰时间及是否有心脏病、糖尿病、或化疗史对造影剂到达腹主动脉峰值大小是否有影响及影响程度。结果造影剂到达腹主动脉峰值大小,在男性平均比女性低;其随年龄、身高、体重、达峰时间的增加而逐渐降低,注射位点在手背静脉其值平均比在肘部静脉低;其不受心率、血压、是否有心脏病、糖尿病或化疗史的影响。参考公式:峰值大小(HU)=383.8400-身高(cm)×1.0909-体重(kg)×0.6760 注射位点×16.7878-达峰时间(s)×1.6882。结论可根据患者的性别、年龄、身高、体重、注射位点和达峰时间来适当调整患者CT血管成像时造影剂用量。     

The adverse effect of treatment prolongation in cervical cancer by high-dose-rate intracavitary brachytherapy.

BACKGROUND AND PURPOSE: The potential risk of prolongation of treatment time in cervical cancer has been reported for many low-dose rate (LDR) studies, with an estimated loss of local control ranging from 0.3 to 1.6% per day of treatment prolongation. Since the treatment schedule for fractionated high-dose rate intracavitary brachytherapy (HDRICB) is not directly comparable with that for low-dose rate studies, this report aims to evaluate the adverse effect of treatment prolongation specifically for cervical cancer treated with HDRICB. MATERIAL AND METHODS: From September 1992 to December 1997, 257 patients diagnosed with uterine cervical cancer (35 Ib, 26 IIa, 122 IIb, 10 IIIa, 57 IIIb, 7 IVa), who underwent external radiotherapy combined with between two and four courses of HDRICB and a minimum of 3 years of follow-up (median 57 months), were analyzed. Treatment consisted of irradiation of the whole pelvis with 44-45 Gy consisting of 22-25 fractions by 5 weeks, with the dose boosted to 54-58 Gy (with central shielding) for patients diagnosed as FIGO stage IIb-IVa bilateral parametrial disease. HDRICB was performed using an Ir-192 remote afterloading technique at 1-week intervals. The standard prescribed dose for each course of HDRICB was 7.2 Gy to point A for three insertions (before July 1995), or 6.0 Gy to point A for four insertions (after July 1995). Total prescribed point A doses (external beam radiotherapy+HDRICB) ranged from 58 to 71.6 Gy (median, 65.6 Gy) for stage IB-IIA, while analogous dosage for larger lesions (stage IIb-IVa) ranged from 59 to 75.6 Gy (median, 65.6 Gy). Kaplan-Meier and multivariate analyses were used to test the effect of treatment time on pelvic control rate (PCR) and cause-specific survival (CSS) at 5 years. RESULTS: Median treatment time was 63 days. For all stages of disease, the 5-year CSS and PCR were significantly different comparing treatment times of less than and greater than or equal to 63 days [83% and 65% (P=0.004], 93% and 83% (P=0.02), respectively]. These associations were also significant for stage Ib/IIa [97% and 79% (P=0.01), and 100% and 87% (P=0.02), respectively), but not for stage IIb [75% and 72% (P=0.79), and 93% and 87% (P=0.83), respectively] or stage III [66% and 49% (P=0.2), and 83% and 72% (P=0.21), respectively]. Multivariate analysis identified three prognostic factors for CSS, stage (P<0.001), tumor response to external RT (P=0.001), and overall treatment time (OTT; P=0.006). Prognostic factors for pelvic failure were stage (P<0.001), tumor response to external RT (P=0.001), and OTT (P=0.03). Prolongation of treatment time resulted in a daily decrease in pelvic control rate of 0.67% overall, and 0.43% for stage Ib-IIa, 0.57% for stage IIb, and 0.73% for stage III patients. CONCLUSION: Analysis of the data from the current study demonstrates that the adverse effect of treatment prolongation was observed later in the treatment course for the high-dose rate (HDR) series compared to the LDR analog, however, treatment-time prolongation still negatively influenced the cause-specific survival and pelvic control rate for both dosage groups.     

军人花粉症106例快速免疫治疗

目的　探讨军人花粉症治疗的有效方法。方法　采用提高起始浓度和快速递增浓度 ,上臂外侧皮下注射的方法对 10 6位军人花粉症患者行快速免疫治疗 ,并对每一位患者治疗前后检测血清中总IgE和嗜酸细胞阳离子蛋白 (ECP)。 结果　治疗前后患者总IgE和ECP值有显著性差异。 10 6例患者经 1～ 3年随访复查 ,78例 2个以上发病季节未发作 ,或仅有轻微鼻痒、眼痒 ,18例症状减轻 ,发病时间缩短半月 ,10例症状无明显改善。显效 82例 ,有效 14例 ,无效 10例 ,总有效率为 90 .5 7%。结论　快速免疫治疗能使患者血清总IgE和ECP下降 ,对军人花粉症疗效好。     

Influence of bradykinin B1 and B2 receptors in the immune response triggered by renal ischemia–reperfusion injury

Bradykinin B1 receptors are exclusively expressed in inflamed tissues. For this reason, they have been related with the outcomes of several pathologies. Ischemia–reperfusion injury is caused by the activation of inflammatory and cytoprotective genes, such as macrophage chemoattractant protein-1 and heme oxygenase-1, respectively. This study was aimed to analyze the involvement of bradykinin B1 and B2 receptors (B1R and B2R) in tissue response after renal ischemia–reperfusion injury. For that, B1R (B1−/−), B2R (B2−/−) knockout animals and its control (wild-type mice, B1B2+/+) were subjected to renal bilateral ischemia, followed by 24, 48 and 120 h of reperfusion. At these time points, blood serum samples were collected for creatinine and urea dosages. Kidneys were harvested for histology and molecular analyses by real-time PCR. At 24 and 48 h of reperfusion, B1−/− group resulted in the lowest serum creatinine and urea levels, indicating less renal damage, which was proved by renal histology. Renal protection associated with B1−/− mice was also related with higher expression of HO-1 and lower expression of MCP-1. In conclusion, the absence of B1R had a protective role against inflammatory responses developed after renal ischemia–reperfusion injury.     

肺炎衣原体感染小鼠肺组织免疫组化表现

目的 :通过研究小鼠肺组织免疫组化 ,对肺炎衣原体肺炎的发病机制进行初步的探讨。　方法 :以肺炎衣原体鼻内或静脉接种Icr小鼠 ,在不同时间点处死动物 ,用免疫组化的方法检测小鼠肺炎衣原体肺炎急性期肺组织的病理改变。　结果 :小鼠吸入肺炎衣原体后第 3、7、14天 ,肺组织中肺炎衣原体的免疫过氧化酶染色呈阳性。炎性肺组织阳性染色呈不均一性 ,为局限性分布。肺炎衣原体抗原阳性表达主要在肺泡巨噬细胞、间质细胞以及支气管周围淋巴组织等部位。静脉接种组引起上述类似改变 ,但程度轻 ,肺炎衣原体抗原阳性表达主要集中在肺泡巨噬细胞及间质细胞中。　结论 :免疫组化法检测小鼠肺炎衣原体肺炎急性期肺组织的病理改变 ,有助于肺炎衣原体肺炎急性期的诊断。肺炎衣原体呼吸道局部感染比血行感染的病理改变更为严重     

对常规体外受精失败后补行卵胞浆内单精子注射的探讨

目的 探讨对可疑受精障碍的常规体外受精(IVF)周期在授精失败后补行卵胞浆内单精子注射(reacue ICSI)的时机及临床效果.方法 对2006年1月至2007年6月在我中心接受常规IVF助孕治疗,可能有受精障碍的13例患者,取卵后6h授精,4h后观察,发现所有卵母细胞均未排出第二极体,立即行补救ICSI.结果 13个周期共154个卵母细胞,其中M Ⅱ期142个;未行补救ICSI的46个均未受精;补救ICSI的96个,受精89个,受精率92.7%,移植13个周期29个胚胎,临床妊娠1例双胎和5例单胎,种植率24.1%.结论 常规IVF受精后4h行补救ICSI可以获得较好的受精率和妊娠率.